Loading…
← CockpitCompetitor Analysis › 688837.SS Evopoint Biosciences Co LtdOpen in the cockpit ↗

Evopoint Biosciences Co Ltd688837.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Mkt cap
$2.08B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$31.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 17.3%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥32.96
1D-3.0%
1W-19.1%
1M-18.1%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %10.4%
52w lowhigh58.3% off high

What Evopoint Biosciences does

Employees: 362

Evopoint Biosciences at a glance

Size Evopoint Biosciences (688837.SS) is a China Health Care company (Biotechnology) with a market value of $2.08B, the 1130th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥32.96 on 18 Nov 2026.

Valuation It trades at 53.6× enterprise value to sales against a peer median of 9.4× (2nd most expensive of 14).

Evopoint Biosciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueCN¥235MCN¥935MCN¥0CN¥0
Revenue growth————
Gross profitn/an/a-CN¥30.8M-CN¥23.3M
EBITDAn/aCN¥254M-CN¥432M-CN¥427M
Net income-CN¥453MCN¥203M-CN¥386M-CN¥427M
Free cash flown/aCN¥119M-CN¥386M-CN¥455M
Capital expendituren/aCN¥62.6MCN¥50.1MCN¥90.1M
Total debtCN¥1.32BCN¥898MCN¥521MCN¥412M

Quarterly statements and history in the cockpit →

Evopoint Biosciences competitors and peer comparison

How Evopoint Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Evopoint Biosciences against its 20 peers (data as of 18 Nov 2026)
Measure688837.SSPeer medianRank in peer set
1-month return-18.1%+1.2%2nd lowest of 21
Distance from 52-week high-58.3%-29.7%2nd lowest of 21
EV / Sales53.6×9.4×2nd most expensive of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a

Questions

Which companies are Evopoint Biosciences's closest peers?
The cockpit's peer set: Alamar Biosciences (ALMR), Aurinia Pharmaceuticals (AUPH), BGI Genomics (300676.SZ), Palvella Therapeutics (PVLA), Zealand Pharma A/S (ZEAL.CO), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), Immunome (IMNM).
Is Evopoint Biosciences expensive compared with its peers?
On ev / sales it trades at 53.6× against a peer median of 9.4×, 2nd most expensive of 14 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.